ClinicalTrials.gg
RecruitingNCT06641414Updated Oct 13, 2026

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

A Phase 3 interventional study of Lisaftoclax (APG-2575) and Azacitidine Injection in Higher-risk Myelodysplastic Syndrome, sponsored by Ascentage Pharma Group Inc.. Recruiting at 155 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 13, 2026First sites in 16 new countriesEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
490
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,363 studies in Myelodysplastic Syndromes with a site in United States — 171 open to participants now, 278 under way, 17 of them phase 3. Myelodysplastic Syndromes · United States.

Planned enrollment
16th of 1,189
490 · median 35
Started
2025
with 37 others
Phase 3
70 of 1,363
5 open now
Primary completion
2029-06
later than 228 of 274 live
Registered
1,306th of 1,363
by date

Among the 1,363 studies in Myelodysplastic Syndromes with a site in United States, this one is the 16th largest by planned enrollment of the 1,189 interventional ones that give a count, is one of 38 that started in 2025, is one of 70 in phase 3, reaches primary completion later than 228 of the 274 other live ones, and was the 1,306th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

171 of the 1,363 studies in Myelodysplastic Syndromes with a site in United States are open now. Recruiting first, the newest first:

166 more — sign in →

All 171 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,363 studies in Myelodysplastic Syndromes with a site in United States, or all of them as a file.
02

Study summary

A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.

Read the detailed description

This study intends to enroll patients with HR-MDS to receive the therapy of lisaftoclax (APG-2575) combined with azacitidine (AZA) or placebo combined with azacitidine.

03

Conditions studied

  • Higher-risk Myelodysplastic Syndrome

Keywords

  • Higher-risk Myelodysplastic Syndrome
  • Lisaftoclax
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed higher-risk MDS.
  2. score of ≤2.
  3. Expected survival ≥ 3 months.
  4. Adequate organ function.
  5. Female subjects of potential have a negative urine or serum pregnancy test before dosing. Subjects of childbearing potential as well as their partners voluntarily use deemed effective by the investigator during the treatment period and for at least six months after the last dose of study drug.
  6. Able to understand and voluntarily sign a written form, which must be signed prior to the performance of any trial-specified study procedures.
  7. Subjects are able to complete study procedures and follow-up examinations.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant other or prior malignancies with disease-free intervals of less than 1 year at the time of signing the .
  2. Have undergone hematopoietic stem cell transplantation.
  3. Use of moderately potent inducers and moderately potent inhibitors of within 14 days prior to the first dose of study drug.
  4. MDS or other conditions that cannot be administered enterally.
  5. Any condition that the subject is deemed to be inappropriate to participate in this study after evaluation by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
490 participants (estimated)

Study arms

  • Experimental
    Lisaftoclax (APG-2575) combined with Azacitidine

    Drug: Lisaftoclax (APG-2575) · Drug: Azacitidine Injection

  • Active comparator
    Placebo combined with Azacitidine

    Drug: azacitidine injection QD: hypodermic or intravenous injection

    Drug: Azacitidine Injection · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival(OS)

    The primary endpoint was overall survival (OS), defined as the time from the date of randomization to the date of death of any cause.

    Time frame: Up to 5 years

Secondary outcomes

  1. Safety evaluation based on the adverse event concurrence

    Number of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) will be evaluated.

    Time frame: Up to 5 years

07

Study locations

143 of 155 sites recruiting
  • Ascentage Investigative Site
    Birmingham, Alabama 35294, United States
    Not yet recruiting
  • Ascentage Investigative Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Ascentage Investigative Site
    Los Angeles, California 90095, United States
    Recruiting
  • Ascentage Investigative Site
    Sacramento, California 95817, United States
    Recruiting
  • Ascentage Investigative Site
    San Diego, California 92093, United States
    Recruiting
  • Ascentage Investigative Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Ascentage Investigative Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Ascentage Investigative Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Ascentage Investigative Site
    Indianapolis, Indiana 46237, United States
    Recruiting
  • Ascentage
    Iowa City, Iowa 52242, United States
    Not yet recruiting
  • Ascentage Investigative Site
    Louisville, Kentucky 40202, United States
    Recruiting
  • Ascentage Investigative Site
    Baltimore, Maryland 21201-1595, United States
    Recruiting
  • Ascentage Investigative Site
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • Ascentage Investigative Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Ascentage Investigative Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Ascentage Investigative Site
    Lincoln, Nebraska 68506, United States
    Recruiting
  • Ascentage Investigative Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Ascentage Investigative Site
    New York, New York 10065, United States
    Recruiting
  • Ascentage Investigative Site
    Rochester, New York 14642, United States
    Recruiting
  • Ascentage Investigative Site
    The Bronx, New York 10467, United States
    Recruiting
  • Ascentage Investigative Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Ascentage Investigative Site
    Durham, North Carolina 27705, United States
    Recruiting
  • Ascentage Investigative Site
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Ascentage Investigative Site
    Cleveland, Ohio 44195, United States
    Recruiting
  • Ascentage Investigative Site
    Columbus, Ohio 43210, United States
    Recruiting
  • Ascentage Investigative Site
    Eugene, Oregon 97401, United States
    Recruiting
  • Ascentage Investigative Site
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • Ascentage Investigative Site
    Providence, Rhode Island 02903, United States
    Not yet recruiting
  • Ascentage Investigative Site
    Austin, Texas 78705, United States
    Recruiting
  • Ascentage Investigative Site
    Houston, Texas 77054, United States
    Recruiting
    • Guillermo Garcia-Manero, M.D. · Principal investigator
  • Ascentage Investigative Site
    Tyler, Texas 75702, United States
    Recruiting
  • Ascentage Investigative Site
    Charlottesville, Virginia 22908, United States
    Recruiting
  • Ascentage Investigative Site
    Manassas, Virginia 20110, United States
    Recruiting
  • Ascentage Investigative Site
    Norfolk, Virginia 23502, United States
    Recruiting
  • Ascentage Investigative Site
    Edmonds, Washington 98026, United States
    Recruiting
  • Ascentage Investigative Site
    Issaquah, Washington 98104, United States
    Recruiting
  • Ascentage Investigative Site
    Seattle, Washington 98104, United States
    Recruiting
  • Ascentage Investigative Site
    Seattle, Washington 98109, United States
    Recruiting
  • Ascentage Investigative Site
    Milwaukee, Wisconsin 53266, United States
    Recruiting
  • Ascentage Investigative Site
    Waukesha, Wisconsin 53188, United States
    Recruiting
  • Ascentage Investigative Site
    Blacktown, Australia 2148, Australia
    Recruiting
  • Ascentage Investigative Site
    Cooloongup, Australia 6168, Australia
    Recruiting
  • Ascentage Investigative Site
    Epping, Australia 3076, Australia
    Recruiting
  • Ascentage Investigative Site
    Heidelberg, Australia 3084, Australia
    Recruiting
  • Ascentage Investigative Site
    Kingswood, Australia 2747, Australia
    Recruiting
  • Ascentage Investigative Site
    Liverpool, Australia 2170, Australia
    Not yet recruiting
  • Ascentage Investigative Site
    Melbourne, Australia 3004, Australia
    Recruiting
  • Ascentage Investigative Site
    Perth, Australia 6000, Australia
    Recruiting
  • Ascentage Investigative Site
    Richmond, Australia 3121, Australia
    Recruiting
  • Ascentage Investigative Site
    Waratah, Australia 2298, Australia
    Recruiting
  • Ascentage Investigative Site
    Antwerp, 2030, Belgium
    Recruiting
  • Ascentage Investigative Site
    Brasschaat, 2930, Belgium
    Recruiting
  • Ascentage Investigative Site
    Bruges, 8000, Belgium
    Recruiting
  • Ascentage Investigative Site
    Ghent, 9000, Belgium
    Recruiting
  • Ascentage Investigative Site
    Leuven, 3001, Belgium
    Recruiting
  • Ascentage Investigative Site
    Roeselare, 8800, Belgium
    Recruiting
  • Ascentage Investigative Site
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Ascentage Investigative Site
    Sofia, 01750, Bulgaria
    Recruiting
  • Ascentage Investigative Site
    Sofia, 01797, Bulgaria
    Recruiting
  • Ascentage Investigative Site
    Sofia, 1431, Bulgaria
    Recruiting
  • Ascentage Investigative Site
    Calgary, Alberta AB T2N, Canada
    Not yet recruiting
  • Ascentage Investigative Site
    Vancouver, British Columbia V6Z 1Y6, Canada
    Not yet recruiting
  • Ascentage Investigative Site
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
  • Ascentage Investigative Site
    Montreal, Quebec H1T 2M4, Canada
    Not yet recruiting
  • Ascentage Investigative Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Ascentage Investigative Site
    Beijing, Beijing Municipality 100033, China
    Recruiting
  • Ascentage Investigative Site
    Brno, 62500, Czechia
    Recruiting
  • Ascentage Investigative Site
    Hradec Králové, 50005, Czechia
    Recruiting
  • Ascentage Investigative Site
    Ostrava, 708 52, Czechia
    Recruiting
  • Ascentage Investigative Site
    Prague, 128 08, Czechia
    Recruiting
  • Ascentage Investigative Site
    Helsinki, Finland 00290, Finland
    Not yet recruiting
  • Ascentage Investigative S
    Kuopio, Finland 70210, Finland
    Recruiting
  • Ascentage Investigative Site
    Tampere, Finland 33520, Finland
    Recruiting
  • Ascentage Investigative Site
    Angers, France 49100, France
    Recruiting
  • Ascentage Investigative Site
    Le Mans, France 72000, France
    Recruiting
  • Ascentage Investigative Site
    Limoges, France 87000, France
    Recruiting
  • Ascentage Investigative Site
    Nantes, France 44000, France
    Recruiting
  • Ascentage Investigative Site
    Nantes, France 44277, France
    Recruiting
  • Ascentage Investigative Site
    Nice, France 06202, France
    Recruiting
  • Ascentage Investigative Site
    Orléans, France 45000, France
    Recruiting
  • Ascentage Investigative Site
    Paris, France 75010, France
    Recruiting
  • Ascentage Investigative Site
    Pessac, France 33604, France
    Recruiting
  • Ascentage Investigative Site
    Poitiers, France 86000, France
    Recruiting
  • Ascentage Investigative Site
    Pontoise, France 95300, France
    Recruiting
  • Ascentage Investigative Site
    Tours, France 37044, France
    Recruiting
  • Ascentage Investigative Site
    Villejuif, France 94800, France
    Recruiting
  • Ascentage Investigative Site
    Berlin, Germany 11203, Germany
    Recruiting
  • Ascentage Investigative Site
    Dresden, Germany 01307, Germany
    Recruiting
  • Ascentage Investigative Site
    Dresden, Germany 01307, Germany
    Not yet recruiting
  • Ascentage Investigative Site
    Düsseldorf, Germany 40479, Germany
    Recruiting
  • Ascentage Investigative Site
    Halle, Germany 06112, Germany
    Recruiting
  • Ascentage Investigative Site
    Leipzig, Germany 04103, Germany
    Recruiting
  • Ascentage Investigative Site
    Stuttgart, Germany 70376, Germany
    Recruiting
  • Ascentage Investigative Site
    Ulm, Germany 89081, Germany
    Not yet recruiting
  • Ascentage Investigative Site
    Alexandroupoli, Greece 68100, Greece
    Recruiting
  • Ascentage Investigative Site
    Athens, Greece 10676, Greece
    Recruiting
  • Ascentage Investigative Site
    Athens, Greece 11527, Greece
    Recruiting
  • Ascentage Investigative Site
    Athens, Greece 11528, Greece
    Recruiting
  • Ascentage Investigative Site
    Athens, Greece 12462, Greece
    Recruiting
  • Ascentage Investigative Site
    Pátrai, Greece 26443, Greece
    Recruiting

Showing the first 100 of 155 sites across 18 countries. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2029, 53 months after the start.

Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's planned 53 months is above that.

Counting every sponsor, half of 46 studies reached it within 48 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2024
First posted
Oct 15, 2024
StartActual
Jan 22, 2025
Primary completionEst.
Jun 2029
CompletionEst.
Dec 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
155 sites added, 2 sites removed — first sites in Australia, Belgium, Bulgaria, Canada, Czechia and 11 more
All 16 countries

Australia, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Norway, Poland, Spain, Sweden, United Kingdom

Show 155 added (40 United States, 17 Spain, 13 France, 13 Italy, 12 United Kingdom, 10 Australia, 8 Germany, 7 Greece, 6 Belgium, 5 Canada, 4 Bulgaria, 4 Czechia, 4 Hungary, 4 Poland, 3 Finland, 3 Norway, 1 China, 1 Sweden)
  • Ascentage Investigative Site · Birmingham, United States
  • Ascentage Investigative Site · Phoenix, United States
  • Ascentage Investigative Site · Los Angeles, United States
  • Ascentage Investigative Site · Sacramento, United States
  • Ascentage Investigative Site · San Diego, United States
  • Ascentage Investigative Site · Aurora, United States
  • Ascentage Investigative Site · Jacksonville, United States
  • Ascentage Investigative Site · Chicago, United States
  • Ascentage Investigative Site · Indianapolis, United States
  • Ascentage · Iowa City, United States
  • Ascentage Investigative Site · Louisville, United States
  • Ascentage Investigative Site · Baltimore, United States
  • Ascentage Investigative Site · Minneapolis, United States
  • Ascentage Investigative Site · Rochester, United States
  • Ascentage Investigative Site · St Louis, United States
  • Ascentage Investigative Site · Lincoln, United States
  • Ascentage Investigative Site · Hackensack, United States
  • Ascentage Investigative Site · New York, United States
  • Ascentage Investigative Site · Rochester, United States
  • Ascentage Investigative Site · The Bronx, United States
  • Ascentage Investigative Site · Charlotte, United States
  • Ascentage Investigative Site · Durham, United States
  • Ascentage Investigative Site · Winston-Salem, United States
  • Ascentage Investigative Site · Cleveland, United States
  • Ascentage Investigative Site · Columbus, United States
  • Ascentage Investigative Site · Eugene, United States
  • Ascentage Investigative Site · Pittsburgh, United States
  • Ascentage Investigative Site · Providence, United States
  • Ascentage Investigative Site · Austin, United States
  • Ascentage Investigative Site · Houston, United States
  • …and 125 more on the registry record
Show 2 removed
  • MD Anderson Cancer Center · Houston, United States
  • Peking University People's Hospital · Beijing, China
Oct 13, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedUncontrolled active infection
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    155 sites added, 2 sites removed — first sites in Australia, Belgium, Bulgaria, Canada, Czechia and 11 more
    All 16 countries

    Australia, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Norway, Poland, Spain, Sweden, United Kingdom

    Show 155 added (40 United States, 17 Spain, 13 France, 13 Italy, 12 United Kingdom, 10 Australia, 8 Germany, 7 Greece, 6 Belgium, 5 Canada, 4 Bulgaria, 4 Czechia, 4 Hungary, 4 Poland, 3 Finland, 3 Norway, 1 China, 1 Sweden)
    • Ascentage Investigative Site · Birmingham, United States
    • Ascentage Investigative Site · Phoenix, United States
    • Ascentage Investigative Site · Los Angeles, United States
    • Ascentage Investigative Site · Sacramento, United States
    • Ascentage Investigative Site · San Diego, United States
    • Ascentage Investigative Site · Aurora, United States
    • Ascentage Investigative Site · Jacksonville, United States
    • Ascentage Investigative Site · Chicago, United States
    • Ascentage Investigative Site · Indianapolis, United States
    • Ascentage · Iowa City, United States
    • Ascentage Investigative Site · Louisville, United States
    • Ascentage Investigative Site · Baltimore, United States
    • Ascentage Investigative Site · Minneapolis, United States
    • Ascentage Investigative Site · Rochester, United States
    • Ascentage Investigative Site · St Louis, United States
    • Ascentage Investigative Site · Lincoln, United States
    • Ascentage Investigative Site · Hackensack, United States
    • Ascentage Investigative Site · New York, United States
    • Ascentage Investigative Site · Rochester, United States
    • Ascentage Investigative Site · The Bronx, United States
    • Ascentage Investigative Site · Charlotte, United States
    • Ascentage Investigative Site · Durham, United States
    • Ascentage Investigative Site · Winston-Salem, United States
    • Ascentage Investigative Site · Cleveland, United States
    • Ascentage Investigative Site · Columbus, United States
    • Ascentage Investigative Site · Eugene, United States
    • Ascentage Investigative Site · Pittsburgh, United States
    • Ascentage Investigative Site · Providence, United States
    • Ascentage Investigative Site · Austin, United States
    • Ascentage Investigative Site · Houston, United States
    • …and 125 more on the registry record
    Show 2 removed
    • MD Anderson Cancer Center · Houston, United States
    • Peking University People's Hospital · Beijing, China
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedUncontrolled active infection
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06641414
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jan 22, 2025
Primary completion
Jun 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Yifan Zhai, M.D., Ph.D.
Contact
yzhai@ascentage.com
+86-20-28068501
Qian Niu, M.D.
Contact
Qian.Niu@ascentage.com
Xiaojun Huang, M.D., Ph.D.
study chair · Peking University People's Hospital
Guillermo Garcia-Manero, M.D.
study chair · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisaftoclax

Start the discussion